Endogenous versus exogenous growth factor regulation of articular chondrocytes

Shuiliang Shi, Albert G. Chan, Scott Mercer, George J. Eckert, Stephen Trippel

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Anabolic growth factors that regulate the function of articular chondrocytes are candidates for articular cartilage repair. Such factors may be delivered by pharmacotherapy in the form of exogenous proteins, or by gene therapy as endogenous proteins. It is unknown whether delivery method influences growth factor effectiveness in regulating articular chondrocyte reparative functions. We treated adult bovine articular chondrocytes with exogenous recombinant insulin-like growth factor-I (IGF-I) and transforming growth factor-beta1 (TGF-β1), or with the genes encoding these growth factors for endogenous production. Treatment effects were measured as change in chondrocyte DNA content, glycosaminoglycan production, and aggrecan gene expression. We found that IGF-I stimulated chondrocyte biosynthesis similarly when delivered by either exogenous or endogenous means. In contrast, exogenous TGF-β1 stimulated these reparative functions, while endogenous TGF-β1 had little effect. Endogenous TGF-β1 became more bioactive following activation of the transgene protein product. These data indicate that effective mechanisms of growth factor delivery for articular cartilage repair may differ for different growth factors. In the case of IGF-I, gene therapy or protein therapy appear to be viable options. In contrast, TGF-β1 gene therapy may be constrained by a limited ability of chondrocytes to convert latent complexes to an active form.

Original languageEnglish
Pages (from-to)54-60
Number of pages7
JournalJournal of Orthopaedic Research
Volume32
Issue number1
DOIs
StatePublished - Jan 2014

Fingerprint

Transforming Growth Factor beta1
Chondrocytes
Intercellular Signaling Peptides and Proteins
Joints
Insulin-Like Growth Factor I
Genetic Therapy
Articular Cartilage
Proteins
Aggrecans
Glycosaminoglycans
Transgenes
Gene Expression
Drug Therapy
DNA
Therapeutics
Genes

Keywords

  • articular chondrocyte
  • gene expression
  • gene transfer
  • insulin-like growth factor-I
  • transforming growth factor-beta1

ASJC Scopus subject areas

  • Orthopedics and Sports Medicine

Cite this

Endogenous versus exogenous growth factor regulation of articular chondrocytes. / Shi, Shuiliang; Chan, Albert G.; Mercer, Scott; Eckert, George J.; Trippel, Stephen.

In: Journal of Orthopaedic Research, Vol. 32, No. 1, 01.2014, p. 54-60.

Research output: Contribution to journalArticle

Shi, Shuiliang ; Chan, Albert G. ; Mercer, Scott ; Eckert, George J. ; Trippel, Stephen. / Endogenous versus exogenous growth factor regulation of articular chondrocytes. In: Journal of Orthopaedic Research. 2014 ; Vol. 32, No. 1. pp. 54-60.
@article{638a2e49e87e4065a4bfcd7d35a16f43,
title = "Endogenous versus exogenous growth factor regulation of articular chondrocytes",
abstract = "Anabolic growth factors that regulate the function of articular chondrocytes are candidates for articular cartilage repair. Such factors may be delivered by pharmacotherapy in the form of exogenous proteins, or by gene therapy as endogenous proteins. It is unknown whether delivery method influences growth factor effectiveness in regulating articular chondrocyte reparative functions. We treated adult bovine articular chondrocytes with exogenous recombinant insulin-like growth factor-I (IGF-I) and transforming growth factor-beta1 (TGF-β1), or with the genes encoding these growth factors for endogenous production. Treatment effects were measured as change in chondrocyte DNA content, glycosaminoglycan production, and aggrecan gene expression. We found that IGF-I stimulated chondrocyte biosynthesis similarly when delivered by either exogenous or endogenous means. In contrast, exogenous TGF-β1 stimulated these reparative functions, while endogenous TGF-β1 had little effect. Endogenous TGF-β1 became more bioactive following activation of the transgene protein product. These data indicate that effective mechanisms of growth factor delivery for articular cartilage repair may differ for different growth factors. In the case of IGF-I, gene therapy or protein therapy appear to be viable options. In contrast, TGF-β1 gene therapy may be constrained by a limited ability of chondrocytes to convert latent complexes to an active form.",
keywords = "articular chondrocyte, gene expression, gene transfer, insulin-like growth factor-I, transforming growth factor-beta1",
author = "Shuiliang Shi and Chan, {Albert G.} and Scott Mercer and Eckert, {George J.} and Stephen Trippel",
year = "2014",
month = "1",
doi = "10.1002/jor.22444",
language = "English",
volume = "32",
pages = "54--60",
journal = "Journal of Orthopaedic Research",
issn = "0736-0266",
publisher = "John Wiley and Sons Inc.",
number = "1",

}

TY - JOUR

T1 - Endogenous versus exogenous growth factor regulation of articular chondrocytes

AU - Shi, Shuiliang

AU - Chan, Albert G.

AU - Mercer, Scott

AU - Eckert, George J.

AU - Trippel, Stephen

PY - 2014/1

Y1 - 2014/1

N2 - Anabolic growth factors that regulate the function of articular chondrocytes are candidates for articular cartilage repair. Such factors may be delivered by pharmacotherapy in the form of exogenous proteins, or by gene therapy as endogenous proteins. It is unknown whether delivery method influences growth factor effectiveness in regulating articular chondrocyte reparative functions. We treated adult bovine articular chondrocytes with exogenous recombinant insulin-like growth factor-I (IGF-I) and transforming growth factor-beta1 (TGF-β1), or with the genes encoding these growth factors for endogenous production. Treatment effects were measured as change in chondrocyte DNA content, glycosaminoglycan production, and aggrecan gene expression. We found that IGF-I stimulated chondrocyte biosynthesis similarly when delivered by either exogenous or endogenous means. In contrast, exogenous TGF-β1 stimulated these reparative functions, while endogenous TGF-β1 had little effect. Endogenous TGF-β1 became more bioactive following activation of the transgene protein product. These data indicate that effective mechanisms of growth factor delivery for articular cartilage repair may differ for different growth factors. In the case of IGF-I, gene therapy or protein therapy appear to be viable options. In contrast, TGF-β1 gene therapy may be constrained by a limited ability of chondrocytes to convert latent complexes to an active form.

AB - Anabolic growth factors that regulate the function of articular chondrocytes are candidates for articular cartilage repair. Such factors may be delivered by pharmacotherapy in the form of exogenous proteins, or by gene therapy as endogenous proteins. It is unknown whether delivery method influences growth factor effectiveness in regulating articular chondrocyte reparative functions. We treated adult bovine articular chondrocytes with exogenous recombinant insulin-like growth factor-I (IGF-I) and transforming growth factor-beta1 (TGF-β1), or with the genes encoding these growth factors for endogenous production. Treatment effects were measured as change in chondrocyte DNA content, glycosaminoglycan production, and aggrecan gene expression. We found that IGF-I stimulated chondrocyte biosynthesis similarly when delivered by either exogenous or endogenous means. In contrast, exogenous TGF-β1 stimulated these reparative functions, while endogenous TGF-β1 had little effect. Endogenous TGF-β1 became more bioactive following activation of the transgene protein product. These data indicate that effective mechanisms of growth factor delivery for articular cartilage repair may differ for different growth factors. In the case of IGF-I, gene therapy or protein therapy appear to be viable options. In contrast, TGF-β1 gene therapy may be constrained by a limited ability of chondrocytes to convert latent complexes to an active form.

KW - articular chondrocyte

KW - gene expression

KW - gene transfer

KW - insulin-like growth factor-I

KW - transforming growth factor-beta1

UR - http://www.scopus.com/inward/record.url?scp=84888066872&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84888066872&partnerID=8YFLogxK

U2 - 10.1002/jor.22444

DO - 10.1002/jor.22444

M3 - Article

C2 - 24105960

AN - SCOPUS:84888066872

VL - 32

SP - 54

EP - 60

JO - Journal of Orthopaedic Research

JF - Journal of Orthopaedic Research

SN - 0736-0266

IS - 1

ER -